



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	17554	ZOVIRAX Aciclovir 500 mg (as sodium) powder for injection vial
ARTG entry for	Medicine Registered	
Sponsor	GlaxoSmithKline Australia Pty Ltd	
Postal Address	PO Box 18095, Melbourne, VIC, 8003 Australia	
ARTG Start Date	15/11/1991	
Product Category	Medicine	
Status	Active	
Approval Area	Drug Safety Evaluation Branch	

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . ZOVIRAX 500 mg powder for injection vial

Product Type	Single Medicine Product	Effective Date	3/07/2002
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

1. Promoting resolution of acute manifestations of mucocutaneous Herpes simplex virus in immunocompromised patients. 2. Treatment of severe initial or primary genital herpes in immune competent patients. 3. Treatment of acute manifestations of Varicella zoster virus infection in immunocompromised patients. 4. Treatment of shingles (Varicella zoster virus infection) in immune competent patients who show severe acute local or systemic manifestations of the disease. INDICATIONS AS AT 20 JULY 1995: Benefits can be expected in patients with rash duration shorter than 72 hours. The use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients. 5. Treatment of Herpes simplex encephalitis.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Not recorded	5 Years	Store below 25 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
5 vials X 500mg	(S4) Prescription Only Medicine

Components

1 . Medicine Component

Dosage Form	Injection, powder for
Route of Administration	Intravenous
Visual Identification	White to off-white freeze dried powder.

Active Ingredients

aciclovir sodium	550 mg
Equivalent: aciclovir	



Australian Government
Department of Health
Therapeutic Goods Administration

500 mg

Other Ingredients (Excipients)

sodium hydroxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary